RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sprint Bioscience Stock

Sprint Bioscience Stocks 2024

Sprint Bioscience Stocks

69.81 M

Ticker

SPRINT.ST

ISIN

SE0006343745

WKN

A14NY2

In 2024, Sprint Bioscience had 69.81 M outstanding stocks, a 0% change from the 69.81 M stocks in the previous year.

The Sprint Bioscience Stocks history

YEARNUMBER OF STOCKS (undefined SEK)
2025e69.81
2024e69.81
202369.81
202242.06
202134.65
202020.7
201915.04
201811.85
201710.15
20169.47
20157.11
20146.54
20136.54
20126.54

Sprint Bioscience shares outstanding

The number of shares was Sprint Bioscience in 2023 — This indicates how many shares 69.81 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sprint Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sprint Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sprint Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sprint Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sprint Bioscience Aktienanalyse

What does Sprint Bioscience do?

The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Sprint Bioscience's Shares Outstanding

Sprint Bioscience's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sprint Bioscience’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sprint Bioscience’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sprint Bioscience’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sprint Bioscience stock

How many stocks are there of Sprint Bioscience?

The current number of stocks of Sprint Bioscience is 69.81 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Sprint Bioscience are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Sprint Bioscience evolved in recent years?

The number of shares of Sprint Bioscience has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Sprint Bioscience as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Sprint Bioscience?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Sprint Bioscience pay?

Over the past 12 months, Sprint Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sprint Bioscience is expected to pay a dividend of 0 SEK.

What is the dividend yield of Sprint Bioscience?

The current dividend yield of Sprint Bioscience is .

When does Sprint Bioscience pay dividends?

Sprint Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sprint Bioscience?

Sprint Bioscience paid dividends every year for the past 0 years.

What is the dividend of Sprint Bioscience?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sprint Bioscience located?

Sprint Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sprint Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sprint Bioscience from 7/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.

When did Sprint Bioscience pay the last dividend?

The last dividend was paid out on 7/22/2024.

What was the dividend of Sprint Bioscience in the year 2023?

In the year 2023, Sprint Bioscience distributed 0 SEK as dividends.

In which currency does Sprint Bioscience pay out the dividend?

The dividends of Sprint Bioscience are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sprint Bioscience

Our stock analysis for Sprint Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sprint Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.